Share this article →

Search articles

Phase III clinical trial in vitiligo seeks participants

 Posted on 4th March 2024  2 minute read

CLINUVEL, a pharmaceutical group specialised in creating commercial products to treat chronic medical conditions, are looking to conduct an investigational therapy using afamelanotide to evaluate its usage as a treatment for vitiligo patients with darker skin types.

What is this study about?

The purpose of this study is to evaluate if afamelanotide combined with Narrow-Band Ultraviolet B (NB-UVB) can improve repigmentation and for how long the pigmentation is maintained after the treatment is complete. Additionally, the study will investigate the safety of this treatment for patients with vitiligo.

What would participants be doing?

This study will last approximately 12 months, with up to one month screening period, five months of treatment and up to six months of follow up. Up to 200 patients with vitiligo from different countries will be enrolled to this study and randomly allocated to one of the two study groups:

  • Narrowband ultraviolet B (NB-UVB) in combination with afamlanotide
  • NB-UVB alone

Who can participate in this study?

You may qualify for this study is you have generalised vitiligo on the face and body for at least 3 months, as well as the following:

  • Aged 12 or more
  • Have medium to dark skin
  • Do not have extensive white hair in your vitiligo patches
  • Do not have a history of melanoma, lentigo maligna or do not have any malignant (cancerous) skin lesions
  • Do not have liver diseases
  • Are not pregnant or breastfeeding

How can I take part?

For more information and recruiting site locations, please contact CLINUVEL directly at or visit this website.

Please support our work! You've enjoyed 1 article this month and we hope you have found it useful. Our work is entirely funded by memberships and donations, so please consider joining our charity today and supporting our work.

Become a Member